



(51) International Patent Classification:

A61K 9/48 (2006.01) *A61K 31/4704* (2006.01)
A61K 31/47 (2006.01) *C07D 215/18* (2006.01)

(21) International Application Number:

PCT/KR2012/005506

(22) International Filing Date:

11 July 2012 (11.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2011-0070680 15 July 2011 (15.07.2011) KR
 10-2011-0111132 28 October 2011 (28.10.2011) KR

(71) Applicant (for all designated States except US): **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do, 445-910 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Yong Il** [KR/KR]; Jinheung Apt. 147-2201, Hwaseo-dong, Paldal-gu, Suwon-si, Gyeonggi-do, 442-718 (KR). **KIM, Dong Ho** [KR/KR]; 202-ho, #1054-26, Namhyeon-dong, Gwanak-gu, Gyeonggi-do, 151-926 (KR). **KWON, Taek Kwan** [KR/KR]; 403-ho, #288-2, Yuljeon-dong, Jang-gu, Suwon-si, Gyeonggi-do, 440-825 (KR). **KIM, Kyeong Soo** [KR/KR]; Cheoncheon Prugio Apt. 113-1902, Cheoncheon-dong, Jang-gu, Suwon-si, Gyeonggi-do, 440-710 (KR). **PARK, Jae Hyun** [KR/KR]; Dongsin Apt. 311-404, Cheongmyeongmaeul, Yeongtong-dong,

Yeongtong-gu, Suwon-si, Gyeonggi-do, 443-470 (KR). **WOO, Jong Soo** [KR/KR]; Cheoncheon Prugio Apt. 120-2303, Cheoncheon-dong, Jang-gu, Suwon-si, Gyeonggi-do 440-330 (KR).

(74) Agent: **FIRSTLAW P.C.**; Trust Tower, 275-7 Yang-jae-Dong, Seocho-Ku, Seoul, 137-739 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE

FIG. 1

Levocetirizine layer

Montelukast layer

(57) Abstract: Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*